Ryan W. Huey, MD, MS
Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine
About Dr. Ryan W. Huey
Dr. Huey is a GI Medical Oncologist who joined MD Anderson Cancer Center in 2016. He sees patients with gastrointestinal cancers and his clinical research focuses on Cancer of Unknown Primary. He has published work describing distinct cohorts of this rare cancer and is actively investigating novel diagnostic and treatment approaches. He holds a Master’s in Science in Health Care Transformation from the University of Texas at Austin, and has a particular interest in the delivery of high-quality, value-based cancer care. He has worked on multiple initiatives looking to optimize the care for patients with cancer, including a study assessing remote patient monitoring for patients receiving chemotherapy, and serves as the Associate Medical Director for the Colorectal Service Line.
Read More
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2023 | University of Texas at Austin, Austin, Texas, US, Health Care Transformation, MS |
| 2012 | University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, US, MD |
| 2008 | Texas Christian University, Fort Worth, Texas, US, Biology, BA |
Postgraduate Training
| 2016-2019 | Clinical Fellowship, Hematology and Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2012-2015 | Clinical Residency, Internal Medicine, Duke University Medical Center, Durham, North Carolina |
Experience & Service
Academic Appointments
Instructor, Duke University Medical Center, Durham, NC, 2015 - 2016
Administrative Appointments/Responsibilities
Associate Medical Director, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Physician Advisor – Operational Medical Director, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - Present
Vizient Champion, Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Scholar, Institute for Cancer Care Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2019
Institutional Committee Activities
Vice Chair, Utilization Review Committee, 2022 - Present
Member, Utilization Review Committee, 2019 - Present
Honors & Awards
| Phi Beta Kappa, Texas Christian University | |
| Jean J. and William Tucker Award for Leadership and Service, Texas Christian University | |
| Janet Perry Award for Overcoming Adversity, Texas Christian University | |
| Podalirian Award, University of Oklahoma College of Medicine | |
| Gold Humanism Honor Society | |
| F. Daniel Duffy, M.D. Internal Medicine Award, University of Oklahoma College of Medicine | |
| NCCN Fellows Recognition Program | |
| LBJ Hospital 2nd Year Fellow of the Year Award, The University of Texas MD Anderson Cancer Center | |
| Conquer Cancer Foundation of ASCO Merit Award | |
| Center for Professionalism Support & Success (CPSS) Award for Professional Excellence (APEX), The University of Texas MD Anderson Cancer Center |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Yousef M, Yousef A, Chowdhury S, Fanaeian MM, Knafl M, Peterson J, Zeineddine M, Alfaro K, Zeineddine F, Goldstein D, Hornstein N, Dasari A, Huey R, Johnson B, Higbie V, Bent A, Kee B, Lee M, Morelli MP, Morris VK, Halperin D, Overman MJ, Parseghian C, Vilar E, Wolff R, Raghav KP, White MG, Uppal A, Sun R, Wang W, Kopetz S, Willis J, Shen JP. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncol None(None):None, 2024. PMID: 39264607.
- Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, Medina-Rosales MN, Reuben A, Holliday EB, Smith GL, Noticewala SS, Nicholas S, Price TR, Martin-Paulpeter RM, Perles LA, Lee SS, Lee MS, Smaglo BG, Huey RW, Willis J, Zhao D, Cohen L, Taniguchi CM, Koay EJ, Katz MHG, Wolff RA, Das P, Pant S, Koong AC, Tang C. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. J Clin Oncol None(None):JCO2400081, 2024. PMID: 39102622.
- Cass SH, Tzeng CD, Prakash LR, Maxwell J, Snyder RA, Kim MP, Huey RW, Smaglo BG, Pant S, Koay EJ, Wolff RA, Lee JE, Katz MHG, Ikoma N. Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer. Ann Surg. e-Pub 2024. PMID: 38506042.
- Johnson B, Morris V, Wang X, Dasari A, Raghav K, Shen JP, Lee MS, Huey R, Parseghian C, Willis J, Wolff R, Drusbosky LM, Overman MJ, Kopetz S. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers (Basel) 16(4), 2024. e-Pub 2024. PMID: 38398128.
- Huey RW, Shah AT, Reddi HV, Dasari P, Topham JT, Hwang H, Dhillon N, Willett A, Smaglo BG, Estrella JS, Rashid A, Matamoros A, Overman MJ, Choquette L, Omerza G, Kelly K, Wang X, Loree JM, Rueter J, Varadhachary GR, Raghav K. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study. JournL National Cancer Inst 115(8):994-997, 2023. PMID: 37202363.
- Morris VK, Jazaeri A, Westin SN, Pettaway C, George S, Huey RW, Grinsfelder M, Shafer A, Johnson B, Vining D, Guo M, Fellman B, Frumovitz M. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist 28(7):618-623, 2023. PMID: 37104874.
- Rogers JE, Sirisaengtaksin A, Leung M, Morris VK, Xiao L, Huey R, Wolff R, Eng C, Vauthey JN, Tzeng CD, Johnson B. Hepatic Metastasectomy in Squamous Cell Carcinoma of the Anal Canal: A Case Series of a Curative Approach. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568706.
- Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precision Oncology 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
- Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist 27(11):952-957, 2022. PMID: 35946836.
- Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
- Parseghian CM, Sanchez EV, Sun R, Eluri M, Morris VK, Johnson B, Morelli MP, Overman MJ, Willis J, Huey R, Singh Raghav KP, Dasari A, Kee BK, Wolff RA, YC Shen JP, Kopetz S. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. Journal of Clinical Oncology 40(16_suppl):3520-3520, 2022. PMID: None.
- Johnson B, Yang D, Dada HI, Morris VK, Wang X, Dasari A, Singh Raghav KP, Kee BK, YC Shen JP, Huey R, Lee MS, Parseghian CM, Le P, Morelli MP, Willis J, Wolff RA, Drusbosky L, Overman MJ, Kopetz S. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. Journal of Clinical Oncology 40(16_suppl):3592-3592, 2022. PMID: None.
- Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer 10(5), 2022. PMID: 35618285.
- Morris, VK, Overman, MJ, Lam, MC, Parseghian, C, Johnson, B, Dasari, NV, Raghav, KS, Kee, BK, Huey, RW, Wolff, RA, Shen, JY, Li, J, Zorrilla, I, Tzeng, CD, Tran Cao, HS, Chun, YS, Newhook, TE, Vauthey, JN, Duose, D, Luthra, R, Haymaker, CL, Kopetz, S. Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer. Cancer Research Communications 2(9):979-986, 2022. PMID: None.
- Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist 26(7):588-596, 2021. e-Pub 2021. PMID: 33783054.
- Raghav K, Hwang H, Jácome AA, Bhang E, Willett A, Huey RW, Dhillon NP, Modha J, Smaglo B, Matamoros A, Estrella JS, Jao J, Overman MJ, Wang X, Greco FA, Loree JM, Varadhachary GR. Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. Clinical Cancer Research 27(12):3414-3421, 2021. e-Pub 2021. PMID: 33858857.
- Allen CJ, Eska JS, Thaker NG, Feeley TW, Kaplan RS, Huey RW, Tzeng CD, Lee JE, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Developing a Value Framework: Utilizing Administrative Data to Assess an Enhanced Care Initiative. Journal of Surgical Research 262:115-120, 2021. e-Pub 2021. PMID: 33561722.
- Huey RW, Smaglo BG, Estrella JS, Matamoros A, Overman MJ, Varadhachary GR, Raghav KPS. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait. Oncologist 26(4):e650-e657, 2021. e-Pub 2021. PMID: 33524217.
- Middleton, LP, Huey, RW, Medeiros, LJ, Miranda, R. Follicular dendritic cell sarcoma in the differential diagnosis of GATA3 positive tumors. Human Pathology: Case Reports 23, 2021. PMID: None.
- Augustyn A, Reed VI, Ahmad N, Bhutani MS, Bloom ES, Bowers JR, Chronowski GM, Das P, Holliday EB, Delclos ME, Huey RW, Koay EJ, Lee SS, Nelson CL, Taniguchi CM, Koong AC, Chun SG. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clinical Translational Radiation Oncology 27:147-151, 2021. e-Pub 2021. PMID: 33665384.
- Allen CJ, Thaker NG, Prakash L, Kruse BC, Feeley TW, Kaplan RS, Huey R, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Communicating Value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative. Ann Surg 273(1):e7-e9, 2021. e-Pub 2020. PMID: 32568750.
- Huey RW, Makawita S, Xiao L, Matamoros A, Estrella JS, Overman MJ, Varadhachary GR, Raghav K. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer 19(1):965, 2019. e-Pub 2019. PMID: 31623602.
- Teague TK, Tan C, Marino JH, Davis BK, Taylor AA, Huey RW, Van De Wiele CJ. CD28 expression redefines thymocyte development during the pre-T to DP transition. Int Immunol 22(5):387-97, 2010. e-Pub 2010. PMID: 20203098.
Other Articles
- Selig BP, Furr JR, Huey RW, Moran C, Alluri VN, Medders GR, Mumm CD, Hallford HG, Mulvihill JJ Cancer chemotherapeutic agents as human teratogens. Birth Defects Res A Clin Mol Teratol 94(8):626-50, 2012. PMID: 22851372.
Editorials
- Lyu HG, Gordon WJ, Huey RW, Katz MHG. Leveraging the 21st Century Cures Act to Improve Cancer Care, Patient Engagement, and Data Collection. JCO Oncology Practice 18(12):788-790, 2022. PMID: 36219810.
- Huey RW, Hawk E, Offodile AC. Mind the Gap: Precision Oncology and Its Potential to Widen Disparities. J Oncol Pract 15(6):301-304, 2019. PMID: 31112478.
Abstracts
- Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. Journal for immunotherapy of cancer 10(5), 2022. PMID: 35618285.
- Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer 10(5), 2022. PMID: 35618285.
- Chun S, Augustyn A, Reed V, Ahmad N, Bhutani M, Bloom ES, Bowers J, Chronowski G, Das P, Holliday E, Delclos M, Huey R, Koay EJ, Lee S, Nelson C, Taniguchi C, Koong A. Implementation of a Stereotactic Body Radiotherapy Program for Unresectable Pancreatic Cancer in an Integrated Community Academic Radiation Oncology Satellite Network. Cureus Journal of Medical Science 14(2), 2022. PMID: None.
Book Chapters
- Huey, RW, Raghav, KS. Treatment Refractory Metastatic Colorectal Cancer, 287-292, 2022.
- Allen CJ, Chen A, Huey RW, Shih YT. Value-Based Oncology. In: None. None. None, None.
- Varadhachary GV, Raghav KP, Huey RW. Carcinoma of Unknown Primary. In: None. None. None, None.
- SiBrito SR, Huey RW. Cancer of Unknown Primary Site. In: The MD Anderson Surgical Oncology Manual. 7. Wolters Kluwer, None.
Grant & Contract Support
| Title: | A Multicenter, Open-label, Phase 1a/b Study of HC-7366 in Subjects With Advanced Solid Tumors |
| Funding Source: | HiberCell, Inc |
| Role: | Co-I |
| Title: | STRATEGIC ALLIANCE: 2020-0902-A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab for Advanced Rare Cancers (SiARa Cancer Study) – Cancer of Unknown Primary (SiARa-CUP) |
| Funding Source: | Innovent Biologics |
| Role: | Collaborator |
Patient Reviews
CV information above last modified September 22, 2024